When the liver tumors were further sub-characterized histologically into HCC, high-grade dysplastic nodules and low-grade dysplastic nodules, there were also no significant differences in the proportions of each tumor subgroup between mice which received no treatment compared to mice which received combination CD5-2 and anti-PD1 antibody (Figure 2E). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.